Polycystic ovarian disease: the adrenal connection.
Polycystic ovarian disease (PCOD) is characterized by hyperandrogenemia, ovulatory dysfunction and polycystic ovaries (PCO). The increased androgen production in PCOD comes primarily from the ovaries. However, in about 40% of patients there is excessive adrenal androgen production (DHEA, DHEA-Sulfate, Androstenedione, Testosterone and Dihydrotestosterone). The contribution of the adrenal in the PCOD is suggested by the presence of adrenal androgen excess in PCO, the presence of PCO in women with enzymatic adrenal hyperplasia as well as in women with adrenal tumors. However, the cause of adrenal androgen hypersecretion is not yet fully understood but it may include endogenous hypersecretion of the zona reticularis of unclear cause, hypersecretion of cortical-androgen-stimulating hormone (CASH), stress, hyperprolactinemia, adrenal enzymatic defects etc. This short review covers the aspects of adrenal androgen hypersecretion in PCOD.
Marouliss
George B
GB
Department of Obstetric and Gynecology Democritus, University of Thrase, University Hospital Dragana, Alexandroupolis, Greece. mlazar@med.duth.gr
Triantafillidis
Ioannis K
IK
D000311:Adrenal Glands / Q000378:metabolism*; D000735:Androstenedione / Q000378:metabolism; D003687:Dehydroepiandrosterone / Q000378:metabolism; D019314:Dehydroepiandrosterone Sulfate / Q000378:metabolism; D003907:Dexamethasone / Q000627:therapeutic use; D013196:Dihydrotestosterone / Q000378:metabolism; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism
D005938:Glucocorticoids; D013196:Dihydrotestosterone; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone